{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:04:03Z","timestamp":1792728243432,"version":"4.5.0"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Ventriculitis is a complication of meningitis (community-acquired or nosocomial) or other central nervous system (CNS) infections such as brain abscess. They are associated with a different spectrum of microorganisms, from resistant gram-negative bacilli to staphylococci, that can lead serious illness with high mortality. Difficult-to-treat resistance (DTR) gram-negative bacilli may increase to 20% of deaths respective to susceptible isolates of the same bacteria. We present the first report of a clinical cured case of DTR Pseudomonas aeruginosa ventriculitis in which cefiderocol penetration into the CNS has been confirmed in blood and cerebrospinal fluid. Cefiderocol might be considered for difficult-to-treat CNS infections in view of the recent new cases published as well as our case.<\/jats:p>","DOI":"10.1093\/ofid\/ofac391","type":"journal-article","created":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T17:23:03Z","timestamp":1659374583000},"source":"Crossref","is-referenced-by-count":27,"title":["Clinical Cure of a Difficult-to-Treat Resistant <i>Pseudomonas aeruginosa<\/i> Ventriculitis Using Cefiderocol: A Case Report and Literature Review"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6187-7442","authenticated-orcid":false,"given":"Cristina","family":"Marcelo","sequence":"first","affiliation":[{"name":"Infectious Disease Unit, Internal Medicine Department, La Paz Institute for Health Research, La Paz University Hospital , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9316-8766","authenticated-orcid":false,"given":"Alejandro","family":"de Gea Grela","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, La Paz University Hospital , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Mart\u00ednez","family":"Palazuelos","sequence":"additional","affiliation":[{"name":"Anesthesiology and Resuscitation Department, La Paz University Hospital , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Veganzones","sequence":"additional","affiliation":[{"name":"Anesthesiology and Resuscitation Department, La Paz University Hospital , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2516-3960","authenticated-orcid":false,"given":"David","family":"Grandioso","sequence":"additional","affiliation":[{"name":"Microbiology Department, La Paz University Hospital , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7241-4208","authenticated-orcid":false,"given":"Beatriz","family":"D\u00edaz-Poll\u00e1n","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, Internal Medicine Department, La Paz Institute for Health Research, La Paz University Hospital , Madrid , Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,8,1]]},"reference":[{"key":"2022081609314986700_ofac391-B1","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s40265-021-01580-4","article-title":"Cefiderocol: a review in serious gram-negative bacterial infections","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"key":"2022081609314986700_ofac391-B2","first-page":"1803","article-title":"Difficult-to-treat resistance in gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents","volume":"67","author":"Kadri","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2022081609314986700_ofac391-B3","author":"European Medicines Agency"},{"key":"2022081609314986700_ofac391-B4","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2022081609314986700_ofac391-B5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2022081609314986700_ofac391-B6","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European Society of Intensive Care Medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2022081609314986700_ofac391-B7","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1093\/cid\/ciaa1478","article-title":"Infectious Diseases Society of America guidance on the treatment of extended-spectrum \u03b2-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa)","volume":"72","author":"Tamma","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2022081609314986700_ofac391-B8","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2022081609314986700_ofac391-B9","doi-asserted-by":"crossref","first-page":"dlab188","DOI":"10.1093\/jacamr\/dlab188","article-title":"Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections","volume":"3","author":"Meschiari","year":"2021","journal-title":"JAC Antimicrobial Resist"},{"key":"2022081609314986700_ofac391-B10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.01437-20","article-title":"Population pharmacokinetic and pharmacokinetic\/pharmacodynamic analyses of cefiderocol, a parenteral siderophore cephalosporin, in patients with pneumonia, bloodstream infection\/sepsis, or complicated urinary tract infection","volume":"65","author":"Kawaguchi","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2022081609314986700_ofac391-B11","doi-asserted-by":"crossref","first-page":"dlac004.043","DOI":"10.1093\/jacamr\/dlac004.043","article-title":"P44 nosocomial neurosurgical meningitis due to XDR Pseudomonas aeruginosa: clinical experience with cefiderocol","volume":"4","author":"Stevenson","year":"2022","journal-title":"JAC Antimicrobial Resist"},{"key":"2022081609314986700_ofac391-B12","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/jac\/dkac066","article-title":"Cerebrospinal fluid concentrations of cefiderocol during the treatment of extensively drug-resistant Pseudomonas aeruginosa ventriculitis","volume":"77","author":"Luque-Paz","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2022081609314986700_ofac391-B13","doi-asserted-by":"crossref","first-page":"ofab216","DOI":"10.1093\/ofid\/ofab216","article-title":"Ventriculitis: a severe complication of central nervous system infections","volume":"8","author":"Luque-Paz","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2022081609314986700_ofac391-B14","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1093\/cid\/ciw861","article-title":"2017 Infectious Diseases Society of America\u2019s clinical practice guidelines for healthcare-associated ventriculitis and meningitis","volume":"64","author":"Tunkel","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2022081609314986700_ofac391-B15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","article-title":"Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis","volume":"19","author":"Cassini","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2022081609314986700_ofac391-B16","article-title":"Clinical breakpoints and dosing of antibiotics","author":"European Committee on Antimicrobial Susceptibility Testing"},{"key":"2022081609314986700_ofac391-B17","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/QCO.0000000000000783","article-title":"Dose optimisation of antibiotics used for meningitis","volume":"34","author":"Heffernan","year":"2021","journal-title":"Curr Opin Infect Dis"},{"key":"2022081609314986700_ofac391-B18","doi-asserted-by":"crossref","first-page":"S645","DOI":"10.1093\/ofid\/ofab466.1300","article-title":"Evaluation of penetration of cefiderocol into cerebrospinal fluid using a rat meningitis model","volume":"8(Suppl 1)","author":"Takemura","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2022081609314986700_ofac391-B19","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1128\/CMR.00007-10","article-title":"Penetration of drugs through the blood-cerebrospinal fluid\/blood-brain barrier for treatment of central nervous system infections","volume":"23","author":"Nau","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"2022081609314986700_ofac391-B20","doi-asserted-by":"crossref","first-page":"e00190-19","DOI":"10.1128\/CMR.00190-19","article-title":"Intrathecal antibacterial and antifungal therapies","volume":"33","author":"Nau","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"2022081609314986700_ofac391-B21","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1080\/23744235.2020.1856921","article-title":"Recurrent neurosurgical site infection by extensively drug-resistant P. aeruginosa treated with cefiderocol: a case report and literature review","volume":"53","author":"Bavaro","year":"2021","journal-title":"Infect Dis (Lond)"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofac391\/45210394\/ofac391.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/8\/ofac391\/45435432\/ofac391.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/8\/ofac391\/45435432\/ofac391.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T09:35:11Z","timestamp":1660642511000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofac391\/6652983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,1]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofac391","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,1]]},"published":{"date-parts":[[2022,8,1]]},"article-number":"ofac391"}}